Table 3

Multivariable model assessing association of fluoroquinolones with aortic aneurysm events

Patient characteristicAdjusted HR95% CIp Value
Current fluoroquinolone use2.242.02 to 2.49<0.001
Demographics
 Sex—male3.233.08 to 3.39<0.001
 Income quintileReferentReferentReferent
  5 (highest)
  41.050.99 to 1.130.117
  31.081.01 to 1.160.017
  21.171.10 to 1.25<0.001
  1 (lowest)1.201.12 to 1.28<0.001
Healthcare utilisation
 Hospital admissions in previous year1.051.01 to 1.100.029
 Physician visits in previous year1.011.00 to 1.01<0.001
Comorbid illnesses
 Diabetes mellitus0.650.61 to 0.70<0.001
 Hypertension1.331.28 to 1.39<0.001
 Atherosclerosis2.202.09 to 2.31<0.001
 Chronic kidney disease1.491.32 to 1.69<0.001
 Chronic obstructive pulmonary disease1.471.37 to 1.59<0.001
 Hypothyroidism1.010.87 to 1.170.873
 Depression1.120.99 to 1.290.083
 Inflammatory bowel disease0.980.73 to 1.300.867
 Malignancy0.920.73 to 1.150.457
 Liver disease0.880.46 to 1.690.698
 Pneumonia in past year1.241.10 to 1.39<0.001
 Urinary tract infection in past year0.910.81 to 1.030.141